Geovax Labs Inc., of Atlanta, said an article published in the open-access Atlas of Science reported that testing in a challenge model showed that its vaccine candidate, GEO-ZM02, provided full protection to mice infected with a lethal dose of Zika virus delivered directly into the brain. The study was funded by a grant from the CDC, which also provided technical assistance.